162 related articles for article (PubMed ID: 21439313)
21. Small Session Size and Big Vial Size: Operational Research Assessing Open Vial Vaccine Wastage at the Service Delivery Points in the Mandalay Region of Myanmar During 2018.
Oo AN; Thekkur P; Thar AMC; Htet KKK; Lin HH
Trop Med Infect Dis; 2020 Apr; 5(2):. PubMed ID: 32326568
[TBL] [Abstract][Full Text] [Related]
22. The real-life number of neonatal doses of Bacille Calmette-Guérin vaccine in a 20-dose vial.
Schaltz-Buchholzer F; Frankel HN; Benn CS
Glob Health Action; 2017; 10(1):1-4. PubMed ID: 28169606
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster.
Littlewood KJ; Ouwens MJ; Sauboin C; Tehard B; Alain S; Denis F
Clin Ther; 2015 Apr; 37(4):830-841.e7. PubMed ID: 25721380
[TBL] [Abstract][Full Text] [Related]
24. A combination vaccine against measles, mumps, rubella and varicella.
Knuf M; Faber J; Barth I; Habermehl P
Drugs Today (Barc); 2008 Apr; 44(4):279-92. PubMed ID: 18536786
[TBL] [Abstract][Full Text] [Related]
25. Varicella vaccines and measles, mumps, rubella, and varicella vaccine.
Bricks LF; Sato HK; Oselka GW
J Pediatr (Rio J); 2006 Jul; 82(3 Suppl):S101-8. PubMed ID: 16826308
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
Leung JH; Hirai HW; Tsoi KK
Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
[TBL] [Abstract][Full Text] [Related]
27. Measles, mumps, rubella prevention: how can we do better?
Kauffmann F; Heffernan C; Meurice F; Ota MOC; Vetter V; Casabona G
Expert Rev Vaccines; 2021 Jul; 20(7):811-826. PubMed ID: 34096442
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
MMR-161 Study Group
Vaccine; 2018 Sep; 36(38):5781-5788. PubMed ID: 30104117
[TBL] [Abstract][Full Text] [Related]
29. Interference between strains in live virus vaccines. II: Combined vaccination with varicella and measles-mumps-rubella vaccine.
Berger R; Just M
J Biol Stand; 1988 Oct; 16(4):275-9. PubMed ID: 2848843
[TBL] [Abstract][Full Text] [Related]
30. Seroprevalence of antibodies to measles, mumps, and rubella among Thai population: evaluation of measles/MMR immunization programme.
Tharmaphornpilas P; Yoocharean P; Rasdjarmrearnsook AO; Theamboonlers A; Poovorawan Y
J Health Popul Nutr; 2009 Feb; 27(1):80-6. PubMed ID: 19248651
[TBL] [Abstract][Full Text] [Related]
31. Similar immunogenicity of measles-mumps-rubella (MMR) vaccine administrated at 8 months versus 12 months age in children.
He H; Chen E; Chen H; Wang Z; Li Q; Yan R; Guo J; Zhou Y; Pan J; Xie S
Vaccine; 2014 Jun; 32(31):4001-5. PubMed ID: 24837773
[TBL] [Abstract][Full Text] [Related]
32. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
Carryn S; Feyssaguet M; Povey M; Di Paolo E
Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
[TBL] [Abstract][Full Text] [Related]
33. How influenza vaccination policy may affect vaccine logistics.
Assi TM; Rookkapan K; Rajgopal J; Sornsrivichai V; Brown ST; Welling JS; Norman BA; Connor DL; Chen SI; Slayton RB; Laosiritaworn Y; Wateska AR; Wisniewski SR; Lee BY
Vaccine; 2012 Jun; 30(30):4517-23. PubMed ID: 22537993
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study.
Klein NP; Abu-Elyazeed R; Povey M; Macias Parra M; Diez-Domingo J; Ahonen A; Korhonen T; Tinoco JC; Weiner L; Marshall GS; Silas PE; Sarpong KO; Ramsey KP; Fling JA; Speicher D; Campos M; Munjal I; Peltier C; Vesikari T; Baccarini C; Caplanusi A; Gillard P; Carryn S; Henry O
J Pediatric Infect Dis Soc; 2020 Apr; 9(2):194-201. PubMed ID: 30849175
[TBL] [Abstract][Full Text] [Related]
35. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Marin M; Güris D; Chaves SS; Schmid S; Seward JF;
MMWR Recomm Rep; 2007 Jun; 56(RR-4):1-40. PubMed ID: 17585291
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live).
Bernstein HH; Eves K; Campbell K; Black SB; Twiggs JD; Reisinger KS; Conti RM; Flodmark CE; Rombo L; Klopfer S; Schödel F; Hartzel J; Kuter BJ;
Pediatrics; 2007 Jun; 119(6):e1299-305. PubMed ID: 17502347
[TBL] [Abstract][Full Text] [Related]
37. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age.
Blatter MM; Klein NP; Shepard JS; Leonardi M; Shapiro S; Schear M; Mufson MA; Martin JM; Varman M; Grogg S; London A; Cambron P; Douha M; Nicholson O; da Costa C; Innis BL
Pediatr Infect Dis J; 2012 Aug; 31(8):e133-40. PubMed ID: 22622699
[TBL] [Abstract][Full Text] [Related]
39. Response to measles-mumps-rubella vaccine in children on dialysis.
Schulman SL; Deforest A; Kaiser BA; Polinsky MS; Baluarte HJ
Pediatr Nephrol; 1992 Mar; 6(2):187-9. PubMed ID: 1571219
[TBL] [Abstract][Full Text] [Related]
40. Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries.
Prymula R; Povey M; Brzostek J; Cabrnochova H; Chlibek R; Czajka H; Leviniene G; Man S; Neamtu M; Pazdiora P; Plesca D; Ruzkova R; Stefkovicova M; Usonis V; Verdanova D; Wysocki J; Casabona G; Habib MA
Vaccine; 2021 May; 39(19):2643-2651. PubMed ID: 33858718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
